OncoMatch/Clinical Trials/NCT03258567
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Is NCT03258567 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nivolumab for epstein-barr virus infections.
Treatment: Nivolumab — Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug. Eligibility: People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or EBV-positive non-Hodgkin lymphomas with no standard therapy Design: Participants will be screened with: Medical history Physical exam Blood and urine tests CAT scan of the chest, abdomen, and pelvis Tumor and bone marrow biopsies (sample taken) Magnetic resonance imaging scan of the brain Lumbar puncture (also known as spinal tap) Positron emission tomography/computed tomography scan with a radioactive tracer Every 2 weeks, participants will get Nivolumab by vein over about 1 hour. They will also have: Physical exam Blood and pregnancy tests Review of side effects and medications During the study, participants will repeat most of the screening tests. They may also have other biopsies. After stopping treatment, participants will have a visit every 3 months for 1 year. Then they will have a visit every 6 months for years 2-5, and then once a year. They will have a physical exam and blood tests. ...
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody
Lab requirements
Blood counts
absolute neutrophil count >= 750/mcL; >= 500/mcL if impairment is due to LPD/NHL; platelets >= 50,000/mcL; >= 25,000/mcL if impairment is due to LPD/NHL (transfusions not permitted); Hemoglobin >= 9g/dL (transfusion permitted)
Kidney function
serum creatinine OR creatinine clearance - Adults: <= 1.5 mg/dL; Minors: serum Cr <= age-adjusted normal OR >= 40 ml/min/1.73m^2
Liver function
total bilirubin < 3.0g/dl OR < 5.0g/dl if Gilbert's syndrome or disease infiltration of the liver is present; AST(SGOT)/ALT(SGPT) <= 3 X institutional upper limit of normal
adequate organ and bone marrow reserve (unless disease-related) as defined below: absolute neutrophil count - >= 750/mcL; >= 500/mcL if impairment is due to LPD/NHL; platelets - >= 50,000/mcL; >= 25,000/mcL if impairment is due to LPD/NHL (transfusions not permitted); Hemoglobin - >= 9g/dL (transfusion permitted); total bilirubin - < 3.0g/dl OR < 5.0g/dl if Gilbert's syndrome or disease infiltration of the liver is present; AST(SGOT)/ALT(SGPT) <= 3 X institutional upper limit of normal; serum creatinine OR creatinine clearance - Adults: <= 1.5 mg/dL; Minors: serum Cr <= age-adjusted normal OR >= 40 ml/min/1.73m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify